Meiji Yasuda Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Meiji Yasuda Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-761	Closed	-$250K	–	648
2024 Q4	$250K	Hold	761	–	–	0.01%	593
2024 Q3	$255K	Buy	+761	New	+$242K	0.01%	591
2022 Q2	–	Sell	-1,712	Closed	-$964K	–	624
2022 Q1	$964K	Sell	1,712 -24	-1%	-$14.5K	0.05%	332
2021 Q4	$1.31M	Buy	1,736 +26	+2%	+$19.5K	0.08%	228
2021 Q3	$1.28M	Buy	1,710 +20	+1%	+$15K	0.09%	212
2021 Q2	$1.09M	Buy	1,690 +20	+1%	+$12.2K	0.05%	249
2021 Q1	$954K	Buy	1,670 +110	+7%	+$65.1K	0.07%	253
2020 Q4	$909K	Buy	+1,560	New	+$888K	0.09%	212

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Meiji Yasuda Asset Management's BIO Position: Q1 2025 in Review

Meiji Yasuda Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 761 shares — an estimated $250K sold.

Meiji Yasuda Asset Management first reported a position in BIO in Q4 2020 and held it in 8 quarters. The position peaked at $1.31M in Q4 2021. 435 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

Meiji Yasuda Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
Meiji Yasuda Asset Management sold 761 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $250K.
Meiji Yasuda Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 8 quarters.
Meiji Yasuda Asset Management's Bio-Rad Laboratories Class A position peaked at $1.31M in Q4 2021.
435 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Meiji Yasuda Asset Management's 13F filing for Q1 2025, filed 16 May 2025.